Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

CNS Oncology
Daniela A BotaApostolos Stathopoulos

Abstract

ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine - composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors. In this double-blinded, randomized, Phase II study bevacizumab-naive patients with recurrent GBM were randomized to receive either ERC1671 in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine® or sargramostim) and cyclophosphamide plus bevacizumab, or placebo plus bevacizumab. Interim results: Median overall survival (OS) of patients treated with ERC1671 plus bevacizumab was 12 months. In the placebo plus bevacizumab group, median OS was 7.5 months. The maximal CD4+ T-lymphocyte count correlated with OS in the ERC1671 but not in the placebo group. The addition of ERC1671/GM-CSF/cyclophosphamide to bevacizumab resulted in a clinically meaningful survival benefit with minimal additional toxicity.

References

Oct 31, 1998·Current Opinion in Immunology·D M Pardoll, S L Topalian
Jun 19, 2004·Hematology·David Z ChangMiguel-Angel Perales
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jan 15, 2008·Cancer Immunology, Immunotherapy : CII·Takuya OsadaMichael A Morse
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Mar 25, 2010·Immunology·K Kai McKinstrySusan L Swain
Apr 2, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lin MinChristiane Ruedl
Oct 1, 2010·Anti-cancer Agents in Medicinal Chemistry·F M HofmanV E J C Schijns
May 26, 2011·Seminars in Immunopathology·Antonella SistiguLaurence Zitvogel
Apr 19, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yushe DangMary L Disis
Aug 9, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Courtney A CraneAndrew T Parsa
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick
Apr 29, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher M JacksonCharles G Drake
Dec 8, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Daniela Alexandru AbramsDaniela A Bota
Jul 2, 2015·Neuro-oncology·Kathryn M FieldMark A Rosenthal
Aug 25, 2015·Current Oncology·O Gallego
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon
Dec 17, 2015·JAMA : the Journal of the American Medical Association·Roger StuppZvi Ram
Jan 8, 2016·Current Neurology and Neuroscience Reports·Kenneth D SwansonEric T Wong
Jan 27, 2016·Clinical Neurology and Neurosurgery·Nicola MontemurroRiccardo Vannozzi
Oct 16, 2016·Journal of Neuro-oncology·Amanda TivnanJochen H M Prehn
Dec 3, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Mário L de LemosSusan Walisser
May 21, 2017·Journal of Neuro-oncology·Roberto Jose DiazRicardo J Komotar
Nov 1, 2017·Human Vaccines & Immunotherapeutics·Ziren KongWenbin Ma
Mar 4, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erik LadomerskyDerek A Wainwright

❮ Previous
Next ❯

Citations

Aug 14, 2019·Current Opinion in Oncology·Valérie DutoitPierre-Yves Dietrich
Jul 30, 2019·Expert Opinion on Investigational Drugs·Casey AnthonyDavid Cory Adamson
Aug 10, 2019·Frontiers in Immunology·Andy S DingMichael Lim
Apr 16, 2020·Cancers·Vilashini RajaratnamShama Parveen Mirza
Dec 20, 2018·International Journal of Molecular Sciences·Thomas C ChenAxel H Schönthal
Feb 1, 2020·Oncoimmunology·Isaure VanmeerbeekAbhishek D Garg
Mar 19, 2020·International Journal of Molecular Sciences·Sabbir KhanJohn F de Groot
Nov 13, 2020·Frontiers in Immunology·Joshua R D PearsonStephanie E B McArdle
Dec 31, 2020·Cancers·Cristina BirzuGiuseppe Lombardi
May 13, 2021·Brain Tumor Pathology·Eiichi IshikawaHiroyoshi Akutsu
Jul 1, 2021·Immunotherapy·Nikolaos CharalampakisDimitrios Schizas

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM-CSF

Methods Mentioned

BETA
surgical resection
dissection

Clinical Trials Mentioned

NCT01903330

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
F Kimura
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
James J VredenburghHenry S Friedman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ramesh K RamanathanDonald L Trump
Progress in Clinical and Biological Research
J C GassonJ F DiPersio
© 2022 Meta ULC. All rights reserved